Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQUA07 Monotherapy and Combination Therapy in ALK-Positive NSCLC
NCT07617337Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Aug 2030
- Countries
- 2
01
Overview
Phase 1, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events up to 48 months, Dose-Limiting Toxicities at 21 days and 1 more. Started Jul 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07617337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617337.